title: Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
abstract: BACKGROUND
  Statins reduce the rate of major cardiovascular events in high-risk patients, but their potential benefit as treatment for heart failure (HF) is less clear.
  
  
  RESULTS
  Patients (n=10,001) with stable coronary disease were randomized to treatment with atorvastatin 80 or 10 mg/d and followed up for a median of 4.9 years. A history of HF was present in 7.8% of patients. A known ejection fraction <30% and advanced HF were exclusion criteria for the study. A predefined secondary end point of the study was hospitalization for HF. The incidence of hospitalization for HF was 2.4% in the 80-mg arm and 3.3% in the 10-mg arm (hazard ratio, 0.74; 95% confidence interval, 0.59 to 0.94; P=0.0116). The treatment effect of the higher dose was more marked in patients with a history of HF: 17.3% versus 10.6% in the 10- and 80-mg arms, respectively (hazard ratio, 0.59; 95% confidence interval, 0.4 to 0.88; P=0.009). Among patients without a history of HF, the rates of hospitalization for HF were much lower: 1.8% in the 80-mg group and 2.0% in the 10-mg group (hazard ratio, 0.87; 95% confidence interval, 0.64 to 1.16; P=0.34). Only one third of patients hospitalized for HF had evidence of preceding angina or myocardial infarction during the study period. Blood pressure was almost identical during follow-up in the treatment groups.
  
  
  CONCLUSIONS
  Compared with a lower dose, intensive treatment with atorvastatin in patients with stable coronary disease significantly reduces hospitalizations for HF. In a post hoc analysis, this benefit was observed only in patients with a history of HF. The mechanism accounting for this benefit is unlikely to be due primarily to a reduction in interim coronary events or differences in blood pressure.
authors.affiliation: Division of Cardiology, University of California, San Francisco School of Medicine, San Francisco, Calif, USA.
authors.forename: Kiran K
authors.initials: KK
authors.lastname: Khush
authors.forename: David D
authors.initials: DD
authors.lastname: Waters
authors.forename: Vera
authors.initials: V
authors.lastname: Bittner
authors.forename: Prakash C
authors.initials: PC
authors.lastname: Deedwania
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Lewis
authors.forename: Nanette K
authors.initials: NK
authors.lastname: Wenger
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage*
chemical_list: D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin